CLSD - Clearside Biomedical Inc

Momentum: Bearish

Recent News

Clearside Biomedical, Inc. ( CLSD ) Reports Q2 Loss, Beats Revenue Estimates

Zacks Commentary • 1 month ago • score: 0.14

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of +50.00% and +87.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Bullish

This Elevance Health Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Clearside Biomedical ( NASDAQ:CLSD ) , Elevance Health ( NYSE:ELV )

Benzinga • 1 month, 4 weeks ago • score: 0.23

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Leerink Partners analyst Whit Mayo downgraded Elevance Health, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Clearside Biomedical, Inc., a biopharmaceutical company, is dedicated to developing and delivering treatments that restore and preserve vision for people with serious eye diseases. The company is headquartered in Alpharetta, Georgia.

52W High

$1.65

52W Low

$0.29

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.11

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-2.84

EV/Revenue (<3 favorable)

4.40

P/S (TTM) (<3 favorable)

6.52

P/B (<3 favorable)

3.93

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

12.88%

Institutions (25–75% balanced)

14.87%

Shares Outstanding

78,510,000

Float

68,114,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

4,166,000

Gross Profit (TTM)

3,769,000

EPS (TTM)

-0.36

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-7.25%

ROE (TTM) (>15% strong)

-13.10%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

4.47

Momentum

Bearish momentum

Value

-0.0458

-0.0456

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025